{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "The clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap and MYC abnormalities, found in all BL, also occur in a subset of DLBCL."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "a phase 3 randomized study of standard immunochemotherapy versus autologous stem cell transplant."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "a phase 3 randomized study of standard immunochemotherapy versus autologous stem cell transplant."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "we identified 260 cases of non-Burkitt, diffuse aggressive B-cell lymphomas"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "MYC positive cases were morphologically and phenotypically heterogeneous and were associated with poor progression-free and overall survival in multivariate analysis."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 6,
    "max_score": 25
  },
  "model": "gpt-4o"
}